Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPEDOX-6 in Advanced Malignancies
NCT07064018Phase 2Recruiting
- Sponsor
- University of California, Irvine
- Start
- Apr 2025
- Primary completion
- Dec 2029
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SPEDOX-6 in soft tissue sarcoma (STS), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), Cervical Cancer (CC), ovarian cancer, sponsored by University of California, Irvine. Started Apr 2025; status: recruiting.
02
Drugs
SPEDOX-6
03
Conditions
soft tissue sarcoma (STS)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)Cervical Cancer (CC)ovarian cancer
Beyond the preview
Go deeper on NCT07064018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07064018.